Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
Public ClinicalTrials.gov record NCT03856216. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation
Study identification
- NCT ID
- NCT03856216
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
- Allogeneic Bone Marrow Transplantation Procedure
- Bendamustine Drug
- Filgrastim-sndz Biological
- Fludarabine Drug
- Inotuzumab Ozogamicin Biological
- Melphalan Drug
- Peripheral Blood Stem Cell Transplantation Procedure
- Rituximab Biological
- Tacrolimus Drug
Procedure · Drug · Biological
Eligibility (public fields only)
- Age range
- 12 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2019
- Primary completion
- Oct 12, 2025
- Completion
- Oct 12, 2025
- Last update posted
- Apr 14, 2026
2019 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03856216, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03856216 live on ClinicalTrials.gov.